Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Discovery & Translation

Science spotlight: RNA-based enzymes for DNA editing; plus XIST-driven autoimmunity and more

BioCentury’s roundup of translational innovations

By Danielle Golovin, Senior Biopharma Analyst
February 3, 2024 2:11 AM UTC

A new genome editing system using RNA-based ribozymes, which are about sixfold smaller than CRISPR/Cas nuclease proteins, could be the starting point for development of next-generation gene editing technologies that are easier to deliver.

Researchers from  Tsinghua University and Chinese Academy of Sciences described in Science a class of enzymes encoded by retrotransposons, dubbed hydrolytic endonucleolytic ribozymes (HYERs), that induced sequence-specific DNA cleavage in mammalian cells. ...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

Chinese Academy of Sciences

Francis Crick Institute

Perha Pharmaceuticals

Roche

Stanford University

Tsinghua University

University College London